AstraZeneca Reports Results of AZD1222 in Primary Analysis of P-III Trial for the Prevention of COVID-19

March 25, 2021 Auto Bot AstraZeneca, AZD1222, Clinical Trials, P-III Trial, Prevention, Report, results 0

Shots:

  • The P-III D8110C00001 study involves assessing AZD1222 vs PBO in 32,449 participants in a ratio (2:1) aged ≥18yrs. across 88 trial centers in the US, Peru and Chile to prevent COVID-19. his primary efficacy analysis included the accrual of 190 symptomatic cases of COVID-19 from total participants
  • The study showed 76% efficacy against symptomatic COVID-19, 85% efficacy in aged ≥65yrs. as its 1EPs and showed 100% efficacy against severe disease and hospitalization in 2EPs. The vaccine was well tolerated with no safety concerns
  • The company will submit EUA to US FDA and also submit the primary analysis for peer-reviewed publication in the coming weeks

Click here ­to­ read full press release/ article | Ref: AstraZeneca | Image: The Economic Times

The post AstraZeneca Reports Results of AZD1222 in Primary Analysis of P-III Trial for the Prevention of COVID-19 first appeared on PharmaShots.